Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons

The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.